Provided by Tiger Trade Technology Pte. Ltd.

Zai Lab Ltd

19.54
+0.24001.24%
Post-market: 19.540.00000.00%19:58 EST
Volume:720.80K
Turnover:14.01M
Market Cap:2.17B
PE:-12.19
High:19.73
Open:19.18
Low:19.02
Close:19.30
52wk High:44.34
52wk Low:15.96
Shares:111.00M
Float Shares:109.37M
Volume Ratio:0.83
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6026
EPS(LYR):-1.6026
ROE:-22.56%
ROA:-12.16%
PB:3.03
PE(LYR):-12.19

Loading ...

Zai Lab (09688) Grants Stock Options and Restricted Share Units

Stock News
·
Dec 03, 2025

A Look at Zai Lab (NasdaqGM:ZLAB) Valuation Following Q3 2025 Results and Pipeline Progress

Simply Wall St.
·
Dec 02, 2025

What Zai Lab (ZLAB)'s Q3 Results and Reaffirmed 2025 Guidance Mean for Shareholders

Simply Wall St.
·
Dec 01, 2025

Zai Lab (09688) Issues 2 Million Shares Under Equity Incentive Plans

Stock News
·
Nov 19, 2025

Zai Lab Ltd Announces Share Options and Restricted Share Units Grants

TIPRANKS
·
Nov 11, 2025

Zai Lab (09688) Grants Stock Options and Restricted Share Units

Stock News
·
Nov 11, 2025

Zai Lab Ltd (1ZLB) Gets a Buy from UBS

TIPRANKS
·
Nov 11, 2025

Stock Track | Zai Lab Plummets 5.05% Pre-Market Amid Broader Decline in Hong Kong's Innovative Drug Sector

Stock Track
·
Nov 07, 2025

Hong Kong Stock Connect Innovative Drug Sector Declines in Afternoon Session, Zai Lab Plunges 10%, 520880 Drops 2% Below 10-Day Moving Average, Intraday Premium Surges

Deep News
·
Nov 07, 2025

Zai Lab (09688) Reports 14% YoY Revenue Growth in Q3, Totaling $116.1 Million

Stock News
·
Nov 06, 2025

Zai Lab Q3 Loss Narrows, Revenue Rises; 2025 Revenue Outlook Revised

MT Newswires Live
·
Nov 06, 2025

Stock Track | Zai Lab Plunges 6.45% in Pre-market as Q3 Earnings Miss Estimates

Stock Track
·
Nov 06, 2025

Earnings Flash (ZLAB) Zai Lab Posts Q3 Revenue $116.1M, vs. FactSet Est of $141.7M

MT Newswires Live
·
Nov 06, 2025

Zai Lab Q3 EPADS $(0.33) Misses $(0.05) Estimate, Sales $116.095M Miss $136.703M Estimate

Benzinga
·
Nov 06, 2025

Zai Lab (09688) Provides Update on Amgen's Bemarituzumab Phase 1b/3 FORTITUDE-102 Clinical Trial

Stock News
·
Nov 05, 2025

Zai Lab (NasdaqGM:ZLAB): Evaluating Valuation Following Promising Trial Results and Phase 3 Progress

Simply Wall St.
·
Nov 02, 2025

JPMorgan Increases Stake in Zai Lab (09688) by Approximately 611,105 Shares at HK$20.56 per Share

Stock News
·
Oct 31, 2025

Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading

MT Newswires Live
·
Oct 30, 2025

Cantor Fitzgerald Remains a Buy on Zai Lab (ZLAB)

TIPRANKS
·
Oct 27, 2025

UBS Initiates “Buy” Rating on Zai Lab (09688) with Clear Catalysts Ahead but Undervalued

Stock News
·
Oct 27, 2025